Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

F, Schettini; N, Chic; F, Brasó-Maristany; L, Paré; T, Pascual; B, Conte; O, Martínez-Sáez; B, Adamo; M, Vidal; E, Barnadas; A, Fernández-Martinez; B, González-Farre; E, Sanfeliu; JM, Cejalvo; G, Perrone; G, Sabarese; F, Zalfa; V, Peg; R, Fasani; P, Villagrasa; J, Gavilá; CH, Barrios; A, Lluch; M, Martín; M, Locci; Placido S, De; A, Prat

doi:10.1038/s41523-020-00208-2

Public

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

Shared by NobleBlocks on Jan 4, 2021 • 12:00 AM UTC

Authors:

Schettini F

Chic N

Brasó-Maristany F

Abstract

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!